Literature DB >> 32522767

COVID-19-associated acute necrotizing myelitis.

Javier Sotoca1, Yensa Rodríguez-Álvarez2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32522767      PMCID: PMC7309521          DOI: 10.1212/NXI.0000000000000803

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
A 69-year-old otherwise healthy woman presented to our clinic with irradiated cervical pain, imbalance, and motor weakness and numbness in the left hand, which had been ongoing for 7 days. Eight days before the onset of these symptoms, she had fever and dry cough. On admission, her neurologic examination showed right facial and left hand hypoesthesia, subtle left hand interosseous weakness, and general hyperreflexia. MRI of the brain was normal, whereas spinal cord images (figure 1, A and D) showed T2-hyperintensity extending from the medulla oblongata to C7, involving most of the cord with diffuse patchy enhancing lesions, suggesting acute transverse myelitis.
Figure

Spinal MRI evolution of LETM with necrotizing area

Sagittal T2-weighted (A–C) and sagittal postcontrast T1-weighted (D–F). Baseline performed (A and D), follow-up 1 week (B and E), and plasmapheresis posttreatment (C and F). A LETM is seen in the cervical spinal cord (A) with patchy enhancement (D). Progressive swelling of the spinal cord and a new necrotizing area (B: arrow) that shows peripheral enhancement (E: arrow). Significant decreases of both myelitis extension (C) and enhancement (F) after plasmapheresis treatment, with necrosis area in evolution. LETM = longitudinal extensive transverse myelitis.

Spinal MRI evolution of LETM with necrotizing area

Sagittal T2-weighted (A–C) and sagittal postcontrast T1-weighted (D–F). Baseline performed (A and D), follow-up 1 week (B and E), and plasmapheresis posttreatment (C and F). A LETM is seen in the cervical spinal cord (A) with patchy enhancement (D). Progressive swelling of the spinal cord and a new necrotizing area (B: arrow) that shows peripheral enhancement (E: arrow). Significant decreases of both myelitis extension (C) and enhancement (F) after plasmapheresis treatment, with necrosis area in evolution. LETM = longitudinal extensive transverse myelitis. Extensive diagnostic workup was performed, showing negative results in blood test for infectious, autoimmune diseases (including myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies), and other potential causes such as vitamin deficits or antiphospholipid syndrome. The patient's CSF analysis showed a traumatic puncture (75 erythrocytes/μL), mild lymphocytic pleocytosis (75 cells/μL, 98% lymphocytes), hyperproteinorraquia of 2.83 g/L, normal adenosine deaminase, and glucose results; IgG index was normal, no oligoclonal bands were present, and bacterial culture and viral multi-PCR test were also negative. The presence of neuronal surface antibodies was also ruled out. Thoracoabdominal CT scan was negative for tumor and lymphadenopathy. SARS-CoV-2 PCR was positive in nasopharyngeal swab and negative in CSF. No cytokine levels were examined neither in serum nor CSF. Treatment with methylprednisolone 1 g IV for 5 days resulted in initial improvement. However, a few days later, her clinical condition worsened markedly: she developed sensory motor deficits in both hands and paraparesis with sphincter incontinence. A new spinal MRI was performed (figure 1, B and E), showing transversally and caudally progression until T6 level with similar enhancement and a new area of central necrosis at the T1 level with peripheral enhancement. Treatment with plasma exchange and other course of methylprednisolone pulses for 5 days with posterior slow oral prednisone tapering resulted in improvement of strength and motor function, until being able to walk with assistance, use electronic devices such as typing on her mobile phone or write with some difficulties, remaining left leg moderate weakness and no sphincter control. After 4 weeks from the clinical onset, she continues improving slowly and performing physical and occupational therapy. Spinal MRI postplasmapheresis (figure 1, C and F) showed substantial decrease in myelitis extension and enhancement, but central necrosis at the C7-T1 level remained unchanged. Acute necrotizing myelitis (ANM) is a rare inflammatory disorder of the spinal cord. Only a few cases have been associated to inflammatory diseases such as neuromyelitis optica or vasculitis, paraneoplastic mechanisms, or adverse effect of new oncologic treatments.[1-3] Spine MRI in ANM usually shows hypointense T1 signal and corresponding increase in T2 signal and, characteristically, hemorrhage, cavitation, and postcontrast enhancement could also be seen. The exact pathogenesis of ANM remains obscure, and analogously to acute necrotizing encephalitis (ANE), an inflammatory response (“cytokine storm”) secondary to a viral infection has been postulated as a possible cause.[4] Human coronaviruses are a group of respiratory viruses that can naturally reach the CNS in humans through hematogenous or neuronal retrograde route and could potentially be associated with neurologic symptoms.[5] A systemic cytokine production due to the SARS-CoV-2 infection has been suggested to contribute to the pathophysiology of severe coronavirus disease 2019 (COVID-19).[6] Recently, a case of ANE caused by the new coronavirus infection has been reported.[7] In our patient, the presence of a longitudinal extensive transverse myelitis with subsequent worsening along with development of a necrotic area, associated with focal swelling, peripheral enhancement, and hypointense foci on T2 images, led us to the diagnosis of ANM in a patient COVID-19 positive. Immunomodulatory treatment such as steroids or plasmapheresis can result in neurologic improvement as the patient reported here. Additional studies are needed to better define the potential role of human coronaviruses in the pathogenesis and the effectiveness of any therapeutic measure in the management of ANM.
  7 in total

1.  Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica?

Authors:  Annette F Okai; Srikanth Muppidi; Ritu Bagla; Thomas P Leist
Journal:  Neurol Res       Date:  2006-04       Impact factor: 2.448

2.  Cytokine release syndrome in severe COVID-19.

Authors:  John B Moore; Carl H June
Journal:  Science       Date:  2020-04-17       Impact factor: 47.728

3.  Cytokine storm of acute necrotizing encephalopathy.

Authors:  Sujay M Kansagra; William B Gallentine
Journal:  Pediatr Neurol       Date:  2011-12       Impact factor: 3.372

4.  Progressive necrotic myelopathy: clinical course in 9 patients.

Authors:  J D Katz; A H Ropper
Journal:  Arch Neurol       Date:  2000-03

Review 5.  Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.

Authors:  Al-Ola Abdallah; Aline Herlopian; Rahul Ravilla; Meghana Bansal; Sowmya Chandra-Reddy; Fade Mahmoud; Shirley Ong; Murat Gokden; Laura Hutchins
Journal:  J Oncol Pharm Pract       Date:  2015-02-23       Impact factor: 1.809

6.  COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features.

Authors:  Neo Poyiadji; Gassan Shahin; Daniel Noujaim; Michael Stone; Suresh Patel; Brent Griffith
Journal:  Radiology       Date:  2020-03-31       Impact factor: 11.105

Review 7.  Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Authors:  Marc Desforges; Alain Le Coupanec; Philippe Dubeau; Andréanne Bourgouin; Louise Lajoie; Mathieu Dubé; Pierre J Talbot
Journal:  Viruses       Date:  2019-12-20       Impact factor: 5.048

  7 in total
  45 in total

Review 1.  Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

Authors:  Shani Witman Tsur; Eli Adrian Zaher; Meydan Tsur; Karolina Kania; Alicja Kalinowska-Łyszczarz
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 2.  COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.

Authors:  Shitiz Sriwastava; Medha Tandon; Sanjiti Podury; Apoorv Prasad; Sijin Wen; Garret Guthrie; Mihir Kakara; Shruti Jaiswal; Roshan Subedi; Mahmoud Elkhooly; Robert P Lisak
Journal:  J Neurol       Date:  2021-05-19       Impact factor: 6.682

3.  Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).

Authors:  Gustavo C Román; Fernando Gracia; Antonio Torres; Alexis Palacios; Karla Gracia; Diógenes Harris
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

4.  MRI negative myelopathy post mild SARS-CoV-2 infection: vasculopathy or inflammatory myelitis?

Authors:  Rory M C Abrams; Farinaz Safavi; Stanley Tuhrim; Allison Navis; Jeremy Steinberger; Susan C Shin
Journal:  J Neurovirol       Date:  2021-06-08       Impact factor: 3.739

Review 5.  COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2.

Authors:  Ariane Lewis; Rajan Jain; Jennifer Frontera; Dimitris G Placantonakis; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neuroimaging       Date:  2021-06-08       Impact factor: 2.324

6.  First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.

Authors:  Joachim Havla; Yannick Schultz; Hanna Zimmermann; Reinhard Hohlfeld; Adrian Danek; Tania Kümpfel
Journal:  J Neurol       Date:  2021-06-11       Impact factor: 4.849

7.  SARS-CoV-2 RNA detection in cerebrospinal fluid: Presentation of two cases and review of literature.

Authors:  María Belén Luis; Nora Fernández Liguori; Pablo Adrián López; Ricardo Alonso
Journal:  Brain Behav Immun Health       Date:  2021-06-08

Review 8.  Infectious and immune-mediated central nervous system disease in 48 COVID-19 patients.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  J Clin Neurosci       Date:  2021-06-01       Impact factor: 1.961

9.  Systematic review of cases of acute myelitis in individuals with COVID-19.

Authors:  Eva C Schulte; Larissa Hauer; Alexander B Kunz; Johann Sellner
Journal:  Eur J Neurol       Date:  2021-07-12       Impact factor: 6.288

10.  COVID-19, Neuropathology, and Aging: SARS-CoV-2 Neurological Infection, Mechanism, and Associated Complications.

Authors:  Rajkumar Singh Kalra; Jaspreet Kaur Dhanjal; Avtar Singh Meena; Vishal C Kalel; Surya Dahiya; Birbal Singh; Saikat Dewanjee; Ramesh Kandimalla
Journal:  Front Aging Neurosci       Date:  2021-06-03       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.